The evidence from various studies is mixed but general consensus is that AI devices can enhance adenoma detection rates (ADR) during colonoscopy, benefiting endoscopists at all levels of experience. Key Points: Clinical Trials vs. Real-World Results: While randomized clinical trials worldwide show an increase in ADR with AI use during colonoscopy, real-world results are varied. Some studies indicate improvement, while others do not. This discrepancy may be due to differences in study designs and implementation methods. Impact on Surveillance and Procedure Quality: AI use in colonoscopy has led to an increase in the proportion of patients requiring intensive surveillance, potentially…
Author: Abhay Panchal
A trio of studies presented at the 2023 annual meeting of the American College of Gastroenterology add support for the role of single-use duodenoscopes in endoscopic retrograde cholangiopancreatography. High Overall Success Rates in Meta-Analysis A systematic literature review revealed that single-use duodenoscopes are associated with a high success rate and promising safety profile in performing endoscopic retrograde cholangiopancreatography procedures (abstract P3717). Data from the 634 patients included in the meta-analysis showed an adjusted pooled procedural completion rate of 94%, which was statistically significant and higher than the American Society for Gastrointestinal Endoscopy threshold of 90% (P<0.001). Of note, there were…
Patients with inflammatory bowel disease are at increased risk for respiratory syncytial virus infection, according to new research presented at the 2023 annual meeting of the American College of Gastroenterology. Although patients with IBD are at an increased risk for developing respiratory infections, research has been limited on RSV in this setting, according to the researchers, led by Ryan A. Smith, MD, a gastroenterology fellow at the University of Wisconsin–Madison. He and his co-investigators wanted to evaluate whether patients with IBD are at an increased risk for RSV infection because that information can assist in informing appropriate vaccination strategies now…
AnX Robotica has announced the FDA clearance of NaviCam ProScan™, a groundbreaking AI-assisted reading tool for small bowel video capsule endoscopy. This clearance, achieved through the rigorous De Novo Submission Process, makes ProScan the first AI-assisted reading tool designed to aid in reviewing small bowel capsule endoscopy images for adult patients suspected of small bowel bleeding. ProScan leverages advanced AI technology to enhance the field of gastroenterology, enabling physicians to efficiently care for their patients. Dr. Cristiano Spada, a gastroenterology expert, praised this development as a significant advancement in small bowel capsule endoscopy, especially for patients with suspected gastrointestinal bleeding.…
EndoSound Inc., a medical technology company, has received 510(k) clearance from the FDA for its EndoSound Vision System® (EVS), a novel Endoscopic Ultrasound (EUS) device. This clearance, following the FDA’s Breakthrough Device designation in July 2021, marks a significant advancement in patient care. The EVS attaches to upper gastrointestinal endoscopes and integrates easily into existing endoscopy centers, making EUS more accessible and economical. It aims to shift the site of care to more efficient settings like ambulatory surgery centers (ASCs), preferred by patients, providers, and payers. The technology is recognized for its patient safety, cost reduction, and increased accessibility to…
HCP Live covers significant developments in the field of gastroenterology during December 2023. Key highlights include: American Gastroenterological Association (AGA) Guidelines: The AGA released two important guidelines in December. The first set of guidelines focuses on the use of biomarkers in managing Crohn’s Disease (CD), offering 11 conditional recommendations based on evidence and expert consensus. These guidelines emphasize the role of serum and fecal biomarkers as surrogates for endoscopic disease activity in CD. The second guideline pertains to the management of pouchitis and inflammatory pouch disorders, marking the first comprehensive evidence-based guideline in this area. Qazi Corner’s Fourth Installment: This…
Watch this amazing recap of The Scope Forward Show 2023 (Season 3). Risks in GI. Non-invasive testing. Breaking rules. Having a backup plan. Stool detection app. Reimbursement for AI. Self driving endoscopy. Lead, don’t get left behind. Endoscopy robots as part of the team. Value of data in GI. Precision medicine. Unconventional ideas. Thank YOU guests for the amazing work you do, for being so candid, and for making The Scope Forward Show one of the most influential podcasts in gastroenterology.
Cigna, which is the fourth largest insurer in the U.S. by membership size, is considering the sale of its Medicare Advantage business. Here are seven additional stories on the company that Becker’s has reported on since Nov. 2:
Join Tim O’Connell, a physician executive. In this episode, we explore the fascinating world of medical-grade AI and its transformative impact on health care. Tim provides valuable insights into the evolution of AI in medicine, recent advancements, and practical applications that are reshaping the future of patient care. Tim O’Connell is a physician executive.He discusses the KevinMD article, “The clinical AI revolution: 3 things to know.”
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a five-year, $3 million grant from the National Cancer Institute. The grant is aimed at developing artificial intelligence (AI) to detect and predict aggressive prostate cancer. This initiative is crucial in helping to avoid unnecessary treatments and their associated negative side effects. Key aspects of the project include: Addressing Overdiagnosis and Overtreatment: Prostate cancer is a common and serious health issue for men. Current screening and risk assessment methods often lead to overdiagnosis and overtreatment. Approximately 90% of people diagnosed with prostate cancer receive treatment, though up to…